These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 9540159)

  • 1. Can expression of CD95 (Fas/APO-1) ligand on grafts or tumor cells prevent their rejection?
    Allison J; Seino K; Yagita H
    Springer Semin Immunopathol; 1998; 19(3):311-22. PubMed ID: 9540159
    [No Abstract]   [Full Text] [Related]  

  • 2. The influence of CD95L expression on tumor rejection in mice.
    Igney FH; Behrens CK; Krammer PH
    Eur J Immunol; 2003 Oct; 33(10):2811-21. PubMed ID: 14515265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transplantation of CD95 ligand-expressing grafts: influence of transplantation site and difficulty in protecting allo- and xenografts.
    Seino K; Kayagaki N; Tsukada N; Fukao K; Yagita H; Okumura K
    Transplantation; 1997 Oct; 64(7):1050-4. PubMed ID: 9381528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice.
    Behrens CK; Igney FH; Arnold B; Möller P; Krammer PH
    J Immunol; 2001 Mar; 166(5):3240-7. PubMed ID: 11207278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Fas ligand expression in promoting escape from immune rejection in a spontaneous tumor model.
    Céfai D; Favre L; Wattendorf E; Marti A; Jaggi R; Gimmi CD
    Int J Cancer; 2001 Feb; 91(4):529-37. PubMed ID: 11251977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A role for CD95 ligand in preventing graft rejection.
    Bellgrau D; Gold D; Selawry H; Moore J; Franzusoff A; Duke RC
    Nature; 1995 Oct; 377(6550):630-2. PubMed ID: 7566174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rejection of Fas ligand-expressing grafts.
    Seino K; Kayagaki N; Fukao K; Okumura K; Yagita H
    Transplant Proc; 1997; 29(1-2):1092-3. PubMed ID: 9123215
    [No Abstract]   [Full Text] [Related]  

  • 8. Accelerated rejection of Fas ligand-expressing heart grafts.
    Takeuchi T; Ueki T; Nishimatsu H; Kajiwara T; Ishida T; Jishage K; Ueda O; Suzuki H; Li B; Moriyama N; Kitamura T
    J Immunol; 1999 Jan; 162(1):518-22. PubMed ID: 9886428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor counterattack--concept and reality.
    Igney FH; Behrens CK; Krammer PH
    Eur J Immunol; 2000 Mar; 30(3):725-31. PubMed ID: 10741386
    [No Abstract]   [Full Text] [Related]  

  • 10. Transgenic expression of CD95 ligand on thyroid follicular cells confers immune privilege upon thyroid allografts.
    Tourneur L; Malassagne B; Batteux F; Fabre M; Mistou S; Lallemand E; Lores P; Chiocchia G
    J Immunol; 2001 Aug; 167(3):1338-46. PubMed ID: 11466351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts.
    Allison J; Georgiou HM; Strasser A; Vaux DL
    Proc Natl Acad Sci U S A; 1997 Apr; 94(8):3943-7. PubMed ID: 9108084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells.
    Shimizu M; Fontana A; Takeda Y; Yagita H; Yoshimoto T; Matsuzawa A
    J Immunol; 1999 Jun; 162(12):7350-7. PubMed ID: 10358186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skin graft rejection elicited by beta 2-microglobulin as a minor transplantation antigen involves multiple effector pathways: role of Fas-Fas ligand interactions and Th2-dependent graft eosinophil infiltrates.
    Surquin M; Le Moine A; Flamand V; Nagy N; Rombaut K; Demoor FX; Stordeur P; Salmon I; Guéry JC; Goldman M; Abramowicz D
    J Immunol; 2002 Jul; 169(1):500-6. PubMed ID: 12077281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Murine heart transgenic Fas ligand expression protects against allograft rejection.
    Zuraff-Perryman LA; Duke RC; Setser E; Nelson DP; Bellgrau D
    Transplant Proc; 2002 Dec; 34(8):3396-8. PubMed ID: 12493481
    [No Abstract]   [Full Text] [Related]  

  • 15. Muscling transplants into mice.
    Wickelgren I
    Science; 1996 Jul; 273(5271):33. PubMed ID: 8658188
    [No Abstract]   [Full Text] [Related]  

  • 16. Expression of Fas and Fas ligand in renal grafts with acute and chronic rejection in the rat model.
    Wang J; Nonomura N; Ichimaru N; Azuma H; Hatori M; Kokado Y; Matsumiya K; Miki T; Takahara S; Okuyama A
    J Interferon Cytokine Res; 1997 Jun; 17(6):369-73. PubMed ID: 9198004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effect of locally produced CD95 ligand.
    Seino K; Kayagaki N; Okumura K; Yagita H
    Nat Med; 1997 Feb; 3(2):165-70. PubMed ID: 9018234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunology. Ways around rejection.
    Vaux DL
    Nature; 1995 Oct; 377(6550):576-7. PubMed ID: 7566165
    [No Abstract]   [Full Text] [Related]  

  • 19. CD95 ligand expression on corneal epithelium and endothelium influences the fates of orthotopic and heterotopic corneal allografts in mice.
    Osawa H; Maruyama K; Streilein JW
    Invest Ophthalmol Vis Sci; 2004 Jun; 45(6):1908-15. PubMed ID: 15161857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of the proinflammatory effects of Fas ligand (CD95L).
    Chen JJ; Sun Y; Nabel GJ
    Science; 1998 Nov; 282(5394):1714-7. PubMed ID: 9831564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.